This announcement is a separate document:
四川百利天恒药业股份有限公司自愿披露关于注射用BL-M17D1（ADC）项目治疗晚期实体瘤获得I期临床试验批准通知书的公告
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily discloses the announcement on obtaining the approval letter for Phase I clinical trial of BL-M17D1 (ADC) project for the treatment of advanced solid tumors.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.